Altair Therapeutics Inc is categorized under Noncommercial Biotechnical Research in Cupertino, CA and active since 2007.
Altair Therapeutics Inc was established in 2007, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Noncommercial Biotechnical Research business, which does work in the B2B market, and is classified as a Noncommercial Biotechnical Research, under code number 541720 by the NAICS.
If you are seeking more information, feel free to contact Joel Martin at the company’s single location by writing to 19200 Stevens Creek Boulevard, Cupertino, California CA 95014 or by phoning No number given. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Altair Therapeutics Inc |
| Contact Person: | Joel Martin |
| Address: | 19200 Stevens Creek Boulevard, Cupertino, California 95014 |
| Annual Revenue (USD): | $500.000 to $999.999 |
| Founded: | 2007 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Noncommercial Biotechnical Research |
| SIC Code: | 8733 |
| NAICS Code: | 541720 |
| Share This Business: |
Altair Therapeutics Inc was started in 2007 to provide professional Noncommercial Biotechnical Research under the SIC code 8733 and NAICS code 541720. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact Joel Martin for inquiries that concern Altair Therapeutics Inc by calling the company number No number given, as your correspondence is most welcome. Additionally, the physical location of the single location of Altair Therapeutics Inc can be found at the coordinates 37.322793,-122.008558 as well as the street address 19200 Stevens Creek Boulevard in Cupertino, California 95014.
For its online presence, you may visit Altair Therapeutics Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.